Argus raised the firm’s price target on United Therapeutics (UTHR) to $560 from $500 and keeps a Buy rating on the shares. Given the strong performance of the company’s Tyvaso franchise, as well as other products in the company’s portfolio, the promising organ manufacturing and transplant program, and the company’s solid balance sheet, the firm sees continued upside for the stock over the next year, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $668 from $640 at Jefferies
- United Therapeutics price target raised to $615 from $600 at Leerink
- United Therapeutics’ Ralinepag Trial Success Boosts PAH Outlook
- United Therapeutics says phase 3 ADVANCE OUTCOMES study met its primary endpoint
- United Therapeutics Earnings Call Signals Growth Ahead